Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients

Introduction: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent, potentially life-threatening angioedema episodes. Despite its severity, including the risk of asphyxiation, HAE often remains underdiagnosed. The disease significantly impacts patient quality of life (QoL...

Full description

Saved in:
Bibliographic Details
Main Authors: Pedro Giavina-Bianchi, MD, PhD, Mara Giavina-Bianchi, MD, PhD, Raquel de Oliveira Martins, Maria Cristina Fortunato, PharmD, Ana Claudia Guersoni, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:World Allergy Organization Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124001248
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850197499584708608
author Pedro Giavina-Bianchi, MD, PhD
Mara Giavina-Bianchi, MD, PhD
Raquel de Oliveira Martins
Maria Cristina Fortunato, PharmD
Ana Claudia Guersoni, MD, PhD
author_facet Pedro Giavina-Bianchi, MD, PhD
Mara Giavina-Bianchi, MD, PhD
Raquel de Oliveira Martins
Maria Cristina Fortunato, PharmD
Ana Claudia Guersoni, MD, PhD
author_sort Pedro Giavina-Bianchi, MD, PhD
collection DOAJ
description Introduction: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent, potentially life-threatening angioedema episodes. Despite its severity, including the risk of asphyxiation, HAE often remains underdiagnosed. The disease significantly impacts patient quality of life (QoL), leading to anxiety, depression, and avoidance behaviors due to the unpredictable nature of attacks. Understanding the perspectives of patients is crucial for identifying unmet needs in managing this complex condition. Objective: This study aimed to gather real-world insights from Brazilian patients with C1 inhibitor deficiency HAE to identify their unmet needs and assess their perceptions of the effectiveness of current care in preventing and treating HAE attacks. Methods: A cross-sectional study utilized a SurveyMonkey questionnaire distributed to HAE patients through ABRANGHE via email. Participants provided informed consent, and their responses were anonymous. The questionnaire, developed with input from experts and patients, covered aspects of HAE diagnosis, treatment experiences, and QoL assessments. Results: The survey included 178 HAE patients, predominantly female (81%), aged 30–50 years (58%), and college-educated (62%). The most common HAE defect was C1–INH deficiency (53%), followed by HAE-nC1INH (23%), with nearly a quarter unaware of their specific defect. Diagnosis delays were prevalent, with a significant number reporting 13–50 attacks annually (33%) and 15% experiencing more than 50 attacks per year. Laryngeal involvement was reported by 26% of respondents. Most patients (69%) attended regular follow-ups, with 72% on prophylactic treatment and 67% managing acute attacks. The most used acute treatment was Icatibant (49%), followed by pdC1INH (24%). However, confusion regarding medication use persisted, with 45% incorrectly believing that oral medications could effectively treat attacks. Key unmet needs identified included improved access to emergency rooms during attacks (73%), better availability of prophylactic treatment (69%), and enhanced access to specialized care (63%). Patients also emphasized the need for psychological support, increased awareness of HAE, and educational initiatives for patients and healthcare providers. Discussion: This study highlighted significant challenges in HAE management among Brazilian patients, particularly concerning delayed diagnosis, misconceptions about treatment, and inadequate access to specialized care and prophylactic treatments. The high frequency of emergency room visits underscores the difficulties in managing the disease. The substantial burden of HAE on QoL emphasizes the urgent need for improved physician education, streamlined diagnostic processes, and equitable access to effective medications and specialized care facilities. Addressing these gaps is crucial to better support HAE patients, improve diagnostic timeliness, enhance treatment efficacy, and ultimately enhance the overall quality of life for individuals living with HAE.
format Article
id doaj-art-7c12c4ad8813488285d0bfa0b03cd072
institution OA Journals
issn 1939-4551
language English
publishDate 2024-11-01
publisher Elsevier
record_format Article
series World Allergy Organization Journal
spelling doaj-art-7c12c4ad8813488285d0bfa0b03cd0722025-08-20T02:13:07ZengElsevierWorld Allergy Organization Journal1939-45512024-11-01171110099210.1016/j.waojou.2024.100992Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patientsPedro Giavina-Bianchi, MD, PhD0Mara Giavina-Bianchi, MD, PhD1Raquel de Oliveira Martins2Maria Cristina Fortunato, PharmD3Ana Claudia Guersoni, MD, PhD4Clinical Immunology and Allergy Division, University of São Paulo School of Medicine, Brazil; Corresponding author. Artur Ramos 178 ap.211, Jd. América, São Paulo, SP, 01454-904, Brazil.Clinical Immunology and Allergy Division, University of São Paulo School of Medicine, Brazil; Hospital Israelita Albert Einstein, São Paulo, BrazilABRANGHE (Associação Brasileira de Portadores de Angioedema Hereditário), BrazilCSL Behring BrazilCSL Behring BrazilIntroduction: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent, potentially life-threatening angioedema episodes. Despite its severity, including the risk of asphyxiation, HAE often remains underdiagnosed. The disease significantly impacts patient quality of life (QoL), leading to anxiety, depression, and avoidance behaviors due to the unpredictable nature of attacks. Understanding the perspectives of patients is crucial for identifying unmet needs in managing this complex condition. Objective: This study aimed to gather real-world insights from Brazilian patients with C1 inhibitor deficiency HAE to identify their unmet needs and assess their perceptions of the effectiveness of current care in preventing and treating HAE attacks. Methods: A cross-sectional study utilized a SurveyMonkey questionnaire distributed to HAE patients through ABRANGHE via email. Participants provided informed consent, and their responses were anonymous. The questionnaire, developed with input from experts and patients, covered aspects of HAE diagnosis, treatment experiences, and QoL assessments. Results: The survey included 178 HAE patients, predominantly female (81%), aged 30–50 years (58%), and college-educated (62%). The most common HAE defect was C1–INH deficiency (53%), followed by HAE-nC1INH (23%), with nearly a quarter unaware of their specific defect. Diagnosis delays were prevalent, with a significant number reporting 13–50 attacks annually (33%) and 15% experiencing more than 50 attacks per year. Laryngeal involvement was reported by 26% of respondents. Most patients (69%) attended regular follow-ups, with 72% on prophylactic treatment and 67% managing acute attacks. The most used acute treatment was Icatibant (49%), followed by pdC1INH (24%). However, confusion regarding medication use persisted, with 45% incorrectly believing that oral medications could effectively treat attacks. Key unmet needs identified included improved access to emergency rooms during attacks (73%), better availability of prophylactic treatment (69%), and enhanced access to specialized care (63%). Patients also emphasized the need for psychological support, increased awareness of HAE, and educational initiatives for patients and healthcare providers. Discussion: This study highlighted significant challenges in HAE management among Brazilian patients, particularly concerning delayed diagnosis, misconceptions about treatment, and inadequate access to specialized care and prophylactic treatments. The high frequency of emergency room visits underscores the difficulties in managing the disease. The substantial burden of HAE on QoL emphasizes the urgent need for improved physician education, streamlined diagnostic processes, and equitable access to effective medications and specialized care facilities. Addressing these gaps is crucial to better support HAE patients, improve diagnostic timeliness, enhance treatment efficacy, and ultimately enhance the overall quality of life for individuals living with HAE.http://www.sciencedirect.com/science/article/pii/S1939455124001248Hereditary angioedemaC1 inhibitor deficiencyMorbidity and mortalitySelf-report questionnaireUnmet needsQuality of life. angioedemas
spellingShingle Pedro Giavina-Bianchi, MD, PhD
Mara Giavina-Bianchi, MD, PhD
Raquel de Oliveira Martins
Maria Cristina Fortunato, PharmD
Ana Claudia Guersoni, MD, PhD
Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
World Allergy Organization Journal
Hereditary angioedema
C1 inhibitor deficiency
Morbidity and mortality
Self-report questionnaire
Unmet needs
Quality of life. angioedemas
title Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
title_full Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
title_fullStr Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
title_full_unstemmed Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
title_short Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients
title_sort unmet needs in the management of hereditary angioedema from the perspective of brazilian patients
topic Hereditary angioedema
C1 inhibitor deficiency
Morbidity and mortality
Self-report questionnaire
Unmet needs
Quality of life. angioedemas
url http://www.sciencedirect.com/science/article/pii/S1939455124001248
work_keys_str_mv AT pedrogiavinabianchimdphd unmetneedsinthemanagementofhereditaryangioedemafromtheperspectiveofbrazilianpatients
AT maragiavinabianchimdphd unmetneedsinthemanagementofhereditaryangioedemafromtheperspectiveofbrazilianpatients
AT raqueldeoliveiramartins unmetneedsinthemanagementofhereditaryangioedemafromtheperspectiveofbrazilianpatients
AT mariacristinafortunatopharmd unmetneedsinthemanagementofhereditaryangioedemafromtheperspectiveofbrazilianpatients
AT anaclaudiaguersonimdphd unmetneedsinthemanagementofhereditaryangioedemafromtheperspectiveofbrazilianpatients